Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Italy To Relax Biosimilar Switching Rules In Cost-Savings Effort

Executive Summary

The move towards greater acceptance of biosimilars is likely to be spurred by new guidance from the Italian regulatory agency AIFA giving more support to biosimilar switching, and by the declaration by a key European medical association that switching infliximab products in IBD patients is “acceptable.”

Advertisement

Related Content

Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?
Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO
Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS119675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel